Apnimed Inc APMD

$18.04 -0.61 (-3.27%)

Valuation

Market cap
905,474,000
Revenue TTM
$38,470,000
Net income TTM
$-128,190,000
PE ratio
0.00
Forward PE
—
Profit margin
-333.22%
Debt to equity
-0.23

Trading

Volume
465,600
Avg volume
—
Day's range
$17.84 – $19.40
Shares out
41,631,000
Stochastic %K
3%
Beta
—
Analysts
Strong Sell
Price target
$50.50

Price

Company profile

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 500 8880
Website
https://apnimed.com
Address
39 John F. Kennedy Street, 4th Floor, Cambridge, United States

Latest news

Stocktwits

KeelinTime Oct 7, 11:16 AM
$APMD
0 replies
bsprelude Oct 6, 8:13 PM
$APMD For all the neurological benefits for getting sleep apnea under control with a pill, I am very excited for APMD’s Oxnimbi. Price target avg of $50 seems justified… Bullish!
0 replies
Rvvrn9 Oct 6, 7:34 PM
$APMD
3 replies
Plungus Oct 6, 6:28 PM
$APMD Down big on tiny volume. This is a steal in the 18 range
0 replies
KeelinTime Oct 6, 4:42 PM
$APMD
0 replies
luklyz Oct 5, 10:24 PM
$IXHL so what are your thoughts on $APMD and their fda application for OSA where they use aroxybutynin as main ingredient same as IXHL. I think this will affect this stock in a bad way. Anyone knows more about that?
4 replies
KeelinTime Oct 2, 4:36 PM
$APMD
0 replies
trading_factory Sep 29, 8:10 PM
$APMD Unknown gem imo
0 replies